HUE029888T2 - Makrofág-migráció-gátló faktort (MIF), mint szív myocardialis depressziót okozó faktort alkalmazó kezelési eljárás és biológiai vizsgálat - Google Patents

Makrofág-migráció-gátló faktort (MIF), mint szív myocardialis depressziót okozó faktort alkalmazó kezelési eljárás és biológiai vizsgálat Download PDF

Info

Publication number
HUE029888T2
HUE029888T2 HUE04782427A HUE04782427A HUE029888T2 HU E029888 T2 HUE029888 T2 HU E029888T2 HU E04782427 A HUE04782427 A HU E04782427A HU E04782427 A HUE04782427 A HU E04782427A HU E029888 T2 HUE029888 T2 HU E029888T2
Authority
HU
Hungary
Prior art keywords
mif
subject
cardiac
antibody
mice
Prior art date
Application number
HUE04782427A
Other languages
English (en)
Inventor
Brett Giroir
Monte Willis
La Cruz Vidal De
Thais Sielecki
Original Assignee
Baxter Int
Baxter Healthcare Sa
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa, Univ Texas filed Critical Baxter Int
Publication of HUE029888T2 publication Critical patent/HUE029888T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (4)

  1. $ÜM% mini mW myoeardiaii* depressziót okozó faktort alkairoazé kezelési eljárás és biológiai vizsgálat SZABADALMI IGÉNYPONTOK 1;. Gyógyszerkészítmény, amely hatékony, égési sérüléssé tirsyff szivmukó·· dés-rendeílenesség kezelésében vagy megelőzésében való alkalmazásra egy ilyen szükséget szenvedó: alanyban; amely magiban fogtaffa: legalább egy entity IF antitestnek a hatékony mennyiségét; és legalább agy gyógyszerészetilag elfogadható hordozót.
  2. Az 1. igénypont szerinti gyógyszerkészítmény, amely továbbá magéban foglal legalább egy CD74 inhibitort is, ahol va CD74 inhibitor tartalmaz iegaiább agy anti~CD74 antitestet
  3. 3, Az 1· sgénypont szerinti gyógyszerkészítmény, amely tov\ábbá magában taglal|a legélPbh égy anii-TNFR. antitest hatékony mennyiségét is.
  4. 4, AZ 1 y vagy 3, igénypont szérintl gyógyszerkészim^ aikalntózáá a szívműködés javulását eredményezi, amelyet az alanyban frakcionáiís róvidöláébél mérünk.
HUE04782427A 2003-08-29 2004-08-30 Makrofág-migráció-gátló faktort (MIF), mint szív myocardialis depressziót okozó faktort alkalmazó kezelési eljárás és biológiai vizsgálat HUE029888T2 (hu)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US49865903P 2003-08-29 2003-08-29
US54705604P 2004-02-25 2004-02-25
US54705704P 2004-02-25 2004-02-25
US54705404P 2004-02-25 2004-02-25
US54705904P 2004-02-25 2004-02-25
US55644004P 2004-03-26 2004-03-26
US10/927,494 US20050202010A1 (en) 2003-08-29 2004-08-27 Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor

Publications (1)

Publication Number Publication Date
HUE029888T2 true HUE029888T2 (hu) 2017-04-28

Family

ID=34280266

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE04782427A HUE029888T2 (hu) 2003-08-29 2004-08-30 Makrofág-migráció-gátló faktort (MIF), mint szív myocardialis depressziót okozó faktort alkalmazó kezelési eljárás és biológiai vizsgálat

Country Status (15)

Country Link
US (3) US20050202010A1 (hu)
EP (2) EP1658037B1 (hu)
JP (3) JP4891769B2 (hu)
CN (2) CN102499984B (hu)
AU (1) AU2004268017B2 (hu)
BR (1) BRPI0413404A (hu)
CA (1) CA2537928C (hu)
CY (1) CY1117925T1 (hu)
DK (1) DK1658037T3 (hu)
ES (1) ES2599032T3 (hu)
HU (1) HUE029888T2 (hu)
MX (2) MXPA06001828A (hu)
PL (1) PL1658037T3 (hu)
PT (1) PT1658037T (hu)
WO (1) WO2005020919A2 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
MXPA06010793A (es) * 2004-03-26 2006-12-19 Cytokine Pharmasciences Inc Compuestos composiciones, procesos de elaboracion, y metodos de uso relacionados a la inhibicion del factor inhibidor de migracion de macrofago.
EP1819731A4 (en) * 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
WO2006116688A2 (en) * 2005-04-26 2006-11-02 Yale University Mif agonists and antagonists and therapeutic uses thereof
CN102088993A (zh) * 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
US20110070184A1 (en) * 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
WO2010056910A2 (en) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
US20110256130A1 (en) * 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
AU2011375306A1 (en) * 2011-08-12 2014-02-27 Alfred Health Method for diagnosis, prognosis or treatment of acute coronary syndrome (ACS) comprising measurement of plasma concentration of macrophage migration inhibitory factor (MIF)
EP2748613B1 (en) 2011-10-07 2021-05-05 Baxalta GmbH Oxmif as a diagnostic marker
KR20150091504A (ko) * 2012-12-07 2015-08-11 백스터 인터내셔널 인코포레이티드 항―ｍｉｆ 항체 세포 이동 검정법
CN105087610A (zh) * 2015-09-11 2015-11-25 中国科学院海洋研究所 文蛤巨噬细胞迁移抑制因子基因及其编码蛋白和应用
JP2018007029A (ja) * 2016-07-01 2018-01-11 株式会社村田製作所 バイアス回路
EP4334469A1 (en) * 2021-05-06 2024-03-13 Abbott Molecular Inc. Compositions and methods for simple sample extraction
CN114288387A (zh) * 2022-02-17 2022-04-08 重庆医科大学 Humanin衍生物HNG在制备治疗心衰药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
DE69813868T2 (de) * 1997-11-05 2004-03-04 The University Of Southern California, Los Angeles Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
JP2003513065A (ja) 1999-10-29 2003-04-08 ザ・ピコワー・インスティチュート・フォー・メディカル・リサーチ Ｍｉｆアンタゴニスト活性を有する化合物
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
US20030235584A1 (en) * 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
CA2455915C (en) * 2001-03-29 2013-05-14 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
EP1411930B1 (en) * 2001-06-08 2013-01-16 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor

Also Published As

Publication number Publication date
CN102499984A (zh) 2012-06-20
WO2005020919A2 (en) 2005-03-10
CN1972713A (zh) 2007-05-30
PT1658037T (pt) 2016-08-30
WO2005020919A3 (en) 2006-11-30
DK1658037T3 (en) 2016-08-29
EP3078386A2 (en) 2016-10-12
JP2011251966A (ja) 2011-12-15
EP1658037A4 (en) 2008-09-10
EP1658037A2 (en) 2006-05-24
MX340217B (es) 2016-06-30
JP5905659B2 (ja) 2016-04-20
ES2599032T3 (es) 2017-01-31
CN102499984B (zh) 2015-02-18
US8747843B2 (en) 2014-06-10
CA2537928C (en) 2015-05-05
EP3078386A3 (en) 2017-01-11
JP4891769B2 (ja) 2012-03-07
JP2007504158A (ja) 2007-03-01
AU2004268017A1 (en) 2005-03-10
US20050202010A1 (en) 2005-09-15
JP2010159267A (ja) 2010-07-22
MXPA06001828A (es) 2007-05-23
PL1658037T3 (pl) 2017-08-31
CY1117925T1 (el) 2017-05-17
AU2004268017B2 (en) 2011-03-17
US20080260723A1 (en) 2008-10-23
EP1658037B1 (en) 2016-05-25
CA2537928A1 (en) 2005-03-10
AU2004268017A2 (en) 2005-03-10
US20150017179A1 (en) 2015-01-15
BRPI0413404A (pt) 2006-10-17
CN1972713B (zh) 2012-02-29

Similar Documents

Publication Publication Date Title
US8747843B2 (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
EP2170366B1 (en) Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
EP2902495A1 (en) Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US8765126B2 (en) Methods of treating complications and disorders associated with G-CSF administration
JP5834004B2 (ja) ループス治療のための方法および組成物
TWI834025B (zh) 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
WO2018124009A1 (ja) 低体温改善剤
JP5978362B2 (ja) 心血管疾患、および２型糖尿病などの代謝疾患の治療のためのｎｋｇ２ｄ阻害剤の使用
KR20180135928A (ko) 간 질환을 치료하거나 예방하는 방법
JP2024008945A (ja) 膵島細胞の増殖を促進する方法
US20160009802A1 (en) Type 3 innate lymphoid cell induced gastrointestinal tract mucosal healing
US20220119523A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
US20220267428A1 (en) BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
KR20150090107A (ko) 중피종의 치료 방법
EP3389704B1 (en) Vaccination against diabetes, obesity and complications thereof
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
WO2023168087A1 (en) Methods and compositions for treating and preventing fibrosis
CN117561078A (zh) 用于评价发展急性covid-19和急性后covid-19的风险的生物标志物
RAT Abstract# 544 THE SURVIVAL BENEFIT OF LIVER TRANSPLANTATION. Robert